We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
Long-term mortality and morbidity results of the Veterans Administration randomized trial of coronary artery bypass surgery.
Circulation 1985 December
The long-term effect of coronary artery bypass grafting on mortality and the incidence of nonfatal myocardial infarction was evaluated in 686 patients in the randomized Veterans Administration study of medical vs surgical treatment for stable angina. Average follow-up was 11.2 years. The 11 year cumulative mortality rates for all patients and for the 595 patients without left main diseases were not significantly different in the two treatment groups. The 7 year mortality rates were 30% in medically assigned and 23% in surgically assigned patients (p = .043) and the 11 year rates were 43% and 42% (p = .45), respectively. The rates in patients without left main disease were 28% for medical and 23% for surgical treatment policy at 7 years (p = .267) and rose to 42% in both groups at 11 years (p = .813). A statistically significant reduction in mortality with surgical policy was found both at 7 and 11 years in high-risk patients without left main disease who had multiple clinical or angiographic risk factors or both. In the subgroup with angiographic high risk, the 7 year mortality rates were 48% in medically assigned and 24% in surgically assigned patients (p = .002); the 11 year rates were 62% and 50%, respectively (p = .026). Corresponding rates in the clinically defined high-risk group were 48% vs 28% (p = .003) at 7 years and 64% vs 51% (p = .015) at 11 years for medical vs surgical policy, respectively. For the subgroup of patients with combined angiographic and clinical high risk, the 7 year mortality rates were 64% for medical and 24% for surgical policy (p = .002); the 11 year rates were 76% and 46%, respectively (p = .005).(ABSTRACT TRUNCATED AT 250 WORDS)
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app